Complications Associated with RSV Infections

New research highlights the effectiveness of RSV preF vaccines in preventing severe respiratory infections in older adults.

Respiratory syncytial virus (RSV) remains a leading cause of acute bronchitis in children, but new research may enable earlier intervention.

Our top RSV content of 2025 included how nirsevimab and clesrovimab changed RSV prevention among younger patients, as well as the positive impact of RSV vaccination in older individuals.

A nationwide Danish cohort study reports cardiovascular events up to 1 year after infection, comparable to that observed with influenza.

More than one-quarter of US adults have a risk factor for severe RSV infection, but their eligibility for the RSV vaccine depends on their age.

RSV vaccines protected older adults against RSV-related hospitalization over 2 seasons, although with less effectiveness for those with immunocompromise or cardiovascular disease.